executives and hedge funds sell.... retail fund managers have been buying the last year.... Who is more likely to know about what nwbo means to some companies long term?
Bottom line it doesn’t bode well for the niche purveyor of the NovoCure device in the UK whom is keeping a wary eye on emerging therapies…..but might explain the “wary eye”